USA flag logo/image

An Official Website of the United States Government

HDAC6-Selective Inhibitors for Pancreatic Cancer Treatment

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88909
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
CA133985
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PSYCHOGENICS, INC.
765 OLD SAW MILL RIVER RD TARRYTOWN, NY 10591-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: HDAC6-Selective Inhibitors for Pancreatic Cancer Treatment
Agency: HHS
Contract: 1R43CA133985-01
Award Amount: $366,682.00
 

Abstract:

DESCRIPTION (provided by applicant): Pancreatic cancer is the fifth leading cause of cancer death in the US. Despite tremendous efforts aimed at understanding its molecular biology, conventional treatment has had little impact. Due to the highly metastatic nature of the disease, surgery is available to only 15- 20% of patients. Thus, the development and characterization of new therapeutic agents that can be used alone or together with conventional therapies is desperately needed. There are 4 classes of HDAC s, and it is hypothesized that increased HDAC activity in cancer cells may contribute to the epigenetic silencing of tumor suppressor genes such as p16, p21 and gelsolin. In fact, treatment of pancreatic cancer cells with the broad spectrum classI/II HDAC inhibitor (HDACI), SAHA, leads to upregulation of p21, growth inhibition and induction of apoptosis. The team of Professor Kozikowski at UIC has recently generated novel classes of HDACIs, several of which show low pM activity toward HDAC6 and HDAC3 in vit ro. Treatment of pancreatic cancer cells with these compounds results in a G1 and/or G2 arrest and induction of apoptosis. In addition, the data indicate that some of these novel HDACIs cause loss of the DNA damage checkpoint kinase, Chk1. It is hypothesiz ed that they can sensitize pancreatic tumor cells to genotoxic agents. We believe that a combination of these HDACIs with DNA damage-inducing agents, such as gemcitabine, will provide significant therapeutic benefit compared to the conventional treatment, gemcitabine alone. To test this hypothesis, we propose to (1) re-synthesize the 12 most active HDACIs made at UIC, and to synthesize 10 new analogs and test them for isoform selectivity; (2) to define biological effects of HDACIs on pancreatic tumor cell p roliferation and survival in vitro; and (3) to determine the in vivo efficacy of the 5 best HDACIs on established pancreatic tumor cell line xenografts with co-administration of gemcitabine. These studies will provide important information regarding the us e of HDACIs in combination with therapeutic agents that cause DNA damage, and valuable structure-activity relationship (SAR) data relevant to the safety and efficacy of these compounds in the treatment of pancreatic cancer, while allowing to gauge the exte nt to which isoform selectivity is required in finding a safe therapy. The biological characterization of the HDACIs presented herein may also allow to better link specific isoforms to tumorigenic events. The two or three best HDACIs identified in this P hase I proposal will be the subject of a Phase II application to fund ADMET work aimed at advancing one of these compounds into clinical studies. PUBLIC HEALTH RELEVANCE: Pancreatic cancer is the fifth leading cause of cancer death in the US and is poorly treatable by conventional chemotherapy, while surgery is available to only 15-20% of patients due to the highly metastatic nature of the disease. The present application aims at investigating the ability of a novel series of inhibitors of histone deacetyl ases (HDACs), which have been shown to inhibit pancreatic cancer cell growth in vitro and lead to apoptosis, to inhibit the growth of pancreatic tumor cell line xenografts in mice in combination with the conventional chemotherapeutic agent, gemcitabine. Po sitive results would lead to a Phase II application to fund ADMET work aimed at advancing one of these compounds into clinical studies.

Principal Investigator:

Business Contact:


bill.fasnacht@psychogenics.com
Small Business Information at Submission:

PSYCHOGENICS, INC.
765 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

EIN/Tax ID: 134034631
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No